Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region
- PMID: 11485624
- DOI: 10.1089/088922201300343753
Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region
Abstract
The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies. Here, we determined whether N-linked glycans of other gp120 domains were also involved in protection of V3 neutralization epitopes. Two molecular clones of HIV-1, one lacking three N-linked glycans of the V1 region (HIV-1(3N/V1)) and another lacking three N-linked glycans of the C2 region (HIV-1(3N/C2)), were created and characterized. gp120 from both mutated viral clones had higher electrophoretic mobilities than gp120 from wild-type virus, confirming loss of N-linked glycans. Wild-type virus and both mutant clones replicated equally well in established T cell lines and all three viruses were able to utilize CXCR4 but not CCR5 as a coreceptor. The induced mutations increased gp120 affinity for CXCR4 but caused no corresponding increase in viral ability to replicate in T cell lines. HIV-1(3N/V1) was neutralized at about 25 times lower concentrations of an antibody to the V3 region than were wild-type virus and HIV-1(3N/C2). Soluble, monomeric gp120 from HIV-1(3N/V1) and wild type virus had identical avidity for the V3 antibody, indicating that the V1 glycans were able to shield V3 only in oligomeric but not monomeric gp120. In conclusion, one or more N-linked glycans of gp120 V1 is engaged in protection of the V3 region from potential neutralizing antibodies, and this effect is dependent on the oligomeric organization of gp120/gp41.
Similar articles
-
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.J Virol. 2005 Jun;79(11):6957-68. doi: 10.1128/JVI.79.11.6957-6968.2005. J Virol. 2005. PMID: 15890935 Free PMC article.
-
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.PLoS Pathog. 2007 Aug 24;3(8):e117. doi: 10.1371/journal.ppat.0030117. PLoS Pathog. 2007. PMID: 17722977 Free PMC article.
-
Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.J Gen Virol. 1996 Apr;77 ( Pt 4):753-8. doi: 10.1099/0022-1317-77-4-753. J Gen Virol. 1996. PMID: 8627264
-
Conformational properties of HIV-1 gp120/V3 immunogenic domains.Curr Med Chem. 2005;12(13):1551-68. doi: 10.2174/0929867054038982. Curr Med Chem. 2005. PMID: 15974987 Review.
-
Synthetic peptides for study of human immunodeficiency virus infection.Appl Biochem Biotechnol. 2002 Jul-Dec;102-103(1-6):41-7. doi: 10.1385/abab:102-103:1-6:041. Appl Biochem Biotechnol. 2002. PMID: 12396109 Review.
Cited by
-
The comparison of genetic variation in the envelope protein between various immunodeficiency viruses and equine infectious anemia virus.Virol Sin. 2012 Aug;27(4):241-7. doi: 10.1007/s12250-012-3253-x. Epub 2012 Jul 28. Virol Sin. 2012. PMID: 22899432 Free PMC article.
-
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.PLoS One. 2010 Apr 21;5(4):e10254. doi: 10.1371/journal.pone.0010254. PLoS One. 2010. PMID: 20421997 Free PMC article.
-
Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.AIDS Res Hum Retroviruses. 2014 Mar;30(3):312-24. doi: 10.1089/aid.2013.0155. Epub 2013 Oct 25. AIDS Res Hum Retroviruses. 2014. PMID: 24090041 Free PMC article.
-
Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.PLoS One. 2015 Oct 22;10(10):e0141233. doi: 10.1371/journal.pone.0141233. eCollection 2015. PLoS One. 2015. PMID: 26491873 Free PMC article.
-
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.J Virol. 2006 Feb;80(3):1414-26. doi: 10.1128/JVI.80.3.1414-1426.2006. J Virol. 2006. PMID: 16415019 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous